New-onset thyrotoxicosis in a patient with anaplastic thyroid carcinoma: a diagnostic challenge.


Journal

Endocrinology, diabetes & metabolism case reports
ISSN: 2052-0573
Titre abrégé: Endocrinol Diabetes Metab Case Rep
Pays: England
ID NLM: 101618943

Informations de publication

Date de publication:
01 Jul 2021
Historique:
received: 13 05 2021
accepted: 27 05 2021
entrez: 1 7 2021
pubmed: 2 7 2021
medline: 2 7 2021
Statut: aheadofprint

Résumé

Anaplastic thyroid cancer (ATC) is the type of thyroid cancer that has the worst prognosis. It usually presents as a rapidly growing cervical mass that generates compressive symptoms. Its association with thyrotoxicosis is rare. A 76-year-old woman, with no contributory history, presented with a 3-month course of fast-growing cervical tumor, associated with tenderness, cough, and weight loss. Physical examination revealed goiter, localized erythema, and a painful and stone tumor dependent on the right thyroid lobe. Due to the malignant findings of the thyroid ultrasound, the patient underwent a thyroid core needle biopsy, which indicated ATC. Laboratory tests revealed leukocytosis, decreased thyroid-stimulating hormone, elevated free thyroxine (fT4), and increased thyroperoxidase (TPO) antibodies. At the beginning, we considered that the etiology of thyrotoxicosis was secondary to subacute thyroiditis (SAT) after SARS-CoV-2 infection, due to the immunochromatography result and chest tomography findings. The result of markedly elevated TPO antibodies left this etiology more remote. Therefore, we suspected Graves' disease as an etiology; however, thyroid histopathology and ultrasound did not show compatible findings. Therefore, we suspect that the main etiology of thyrotoxicosis in the patient was the destruction of the thyroid follicles caused by a rapid invasion of malignant cells, which is responsible for the consequent release of preformed thyroid hormone. ATC is a rare endocrine neoplasm with high mortality; it may be associated with thyrotoxicosis, whose etiology can be varied; therefore, differential diagnosis is important for proper management. Anaplastic thyroid cancer is the thyroid cancer with the worst prognosis and the highest mortality. The association of anaplastic thyroid cancer with thyrotoxicosis is rare, and a differential diagnosis is necessary to provide adequate treatment. Due to the current pandemic, in patients with thyrotoxicosis, it is important to rule out SARS-CoV-2 as an etiology. Anaplastic thyroid cancer, due to its aggressive behavior and rapid growth, can destroy thyroid follicular cells, generating preformed thyroid hormone release, being responsible for thyrotoxicosis.

Identifiants

pubmed: 34196279
doi: 10.1530/EDM-21-0053
pii: EDM210053
pmc: PMC8284955
doi:
pii:

Types de publication

Journal Article

Langues

eng

Références

Endocr Relat Cancer. 2019 Jul;26(7):R395-R413
pubmed: 31026810
Front Oncol. 2017 Apr 10;7:53
pubmed: 28443243
Endocr Pract. 2005 Jul-Aug;11(4):281-4
pubmed: 16006301
Front Endocrinol (Lausanne). 2018 Dec 03;9:737
pubmed: 30559722
Int J Clin Pract. 2021 May;75(5):e14003
pubmed: 33403716
Eur Thyroid J. 2021 Feb;9(6):324-328
pubmed: 33708634
JAMA Oncol. 2020 Sep 1;6(9):1397-1404
pubmed: 32761153
Mayo Clin Proc. 1985 Jan;60(1):51-8
pubmed: 3965822
J Thyroid Res. 2012;2012:525936
pubmed: 22577596
Lancet Diabetes Endocrinol. 2020 Sep;8(9):739-741
pubmed: 32738929
Endocr Pathol. 2005 Fall;16(3):245-50
pubmed: 16299408
Am Surg. 2020 May;86(5):516-518
pubmed: 32684039
Front Immunol. 2017 May 09;8:521
pubmed: 28536577
Int J Infect Dis. 2021 Mar;104:159-163
pubmed: 33383223
Nat Rev Endocrinol. 2017 Nov;13(11):644-660
pubmed: 28707679
Am J Med. 1983 Oct;75(4):702-4
pubmed: 6624779
Thyroid. 2021 Mar;31(3):337-386
pubmed: 33728999
J Clin Endocrinol Metab. 2020 Jul 1;105(7):
pubmed: 32436948
Endokrynol Pol. 2018;69(1):28-31
pubmed: 29319130

Auteurs

Marcio José Concepción Zavaleta (MJ)

Division of Endocrinology, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru.

Sofia Pilar Ildefonso Najarro (SP)

Division of Endocrinology, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru.

Esteban Alberto Plasencia Dueñas (EA)

Division of Endocrinology, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru.

María Alejandra Quispe Flores (MA)

Division of Endocrinology, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru.

Diego Martín Moreno Marreros (DM)

Facultad de Medicina de la Universidad Nacional de Trujillo, Trujillo, Peru.

Luis Alberto Concepción Urteaga (LA)

Division of Neumology, Hospital Regional Docente de Trujillo, Trujillo, Peru.

Laura Esther Luna Victorio (LE)

Division of Endocrinology, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru.

Freddy Valdivia Fernández Dávila (FV)

Division of Endocrinology, Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru.

Classifications MeSH